IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11198730 B1

PDFFull Text
Date of Patent:
Dec. 14, 2021

Filed:

Aug. 10, 2017

Anti-lag-3 antibody

Applicants:

National University Corporation Hokkaido University, Hokkaido, JP;

Fuso Pharmaceutical Industries, Ltd., Osaka, JP;

Inventors:

Satoru Konnai, Hokkaido, JP;

Kazuhiko Ohashi, Hokkaido, JP;

Shiro Murata, Hokkaido, JP;

Tomohiro Okagawa, Hokkaido, JP;

Asami Nishimori, Hokkaido, JP;

Naoya Maekawa, Hokkaido, JP;

Yasuhiko Suzuki, Hokkaido, JP;

Chie Nakajima, Hokkaido, JP;

Assignees:

Fuso Pharmaceutical Industries, Ltd., Osaka, JP;

National University Corporation Hokkaido University, Hokkaido, JP;

Attorney:

Schwegman Lundberg & Woessner, P.A.

Primary Examiner:

Michael Szperka

Assistant Examiner:

Lia E Taylor

Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/46 (2006.01); A61P 31/10 (2006.01); A61P 31/06 (2006.01); A61P 15/14 (2006.01); A61P 35/02 (2006.01); A61P 33/02 (2006.01); C12N 15/09 (2006.01); A61P 31/00 (2006.01); A61K 39/395 (2006.01); C12N 5/10 (2006.01); A61P 31/04 (2006.01); A61P 35/00 (2006.01); C12N 15/85 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 39/395 (2013.01); A61P 15/14 (2018.01); A61P 31/00 (2018.01); A61P 31/04 (2018.01); A61P 31/06 (2018.01); A61P 31/10 (2018.01); A61P 33/02 (2018.01); A61P 35/00 (2018.01); A61P 35/02 (2018.01); C07K 16/28 (2013.01); C07K 16/46 (2013.01); C12N 5/10 (2013.01); C12N 15/09 (2013.01); C12N 15/85 (2013.01); C12N 2015/8518 (2013.01);
Abstract

The present invention provides an anti-LAG-3 antibody capable of repeated administration even to animals other than rat. An anti-LAG-3 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLDSDGNTY (SEQ ID NO: 16), CDR2 having the amino acid sequence of SVS and CDR3 having the amino acid sequence of MQATHVPFT (SEQ ID NO: 17) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GFDFDTYP (SEQ ID NO: 18), CDR2 having the amino acid sequence of ITIKTHNYAT (SEQ ID NO: 19) and CDR3 having the amino acid sequence of NREDFDY (SEQ ID NO: 20) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-LAG-3 antibody as an active ingredient. A method for preparing the above anti-LAG-3 antibody is also provided.

Find Patent Forward Citations

Loading…